Homologous Recombination News and Research

RSS

IDT to demonstrate CRISPR expertise at European-focused events

As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.

From Integrated DNA Technologies 22 Oct 2018

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

A study comparing DNA and RNA data from Nigerian breast cancer patients to patients in a United States database found that certain aggressive molecular features were far more prevalent in tumors from Nigerian women than in black or white American women.

16 Oct 2018

Researchers develop molecule that makes cancer cells sensitive to radiotherapy

Researchers from Karolinska Institutet and Kancera AB have developed a molecule that makes cancer cells sensitive to radiotherapy. In a study published in Nature Communications, the researchers describe a new way to block cancer cells' ability to repair their DNA and thus stop the survival of cancer cells.

25 Sep 2018

New protein complex may explain why patients develop resistance to novel anti-cancer drugs

A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.

25 Jul 2018

YCC researchers suggest promising treatment for two rare inherited cancer syndromes

Studying two rare inherited cancer syndromes, Yale Cancer Center scientists have found the cancers are driven by a breakdown in how cells repair their DNA.

17 Jul 2018

Genetic subset of prostate cancer may benefit from combination checkpoint immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer.

25 Jun 2018

LogicBio team to present data on preclinical effectiveness of GeneRide platform

LogicBio Therapeutics, Inc., a genetic medicine company founded to develop safe medicines with lasting therapeutic benefit for children with life-threatening diseases, today announced it will be presenting data on the company's technology and robust preclinical pipeline at the annual meeting of the American Society of Gene & Cell Therapy at the Hilton Chicago, from May 16-19, 2018.

14 May 2018

Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients

People with tough-to-treat triple negative breast cancer, whose tumors also don't allow for double-strand DNA repair, fare better when treated with a common adjuvant breast cancer chemotherapy combination, according to results from a SWOG clinical trial.

20 Mar 2018

Researchers identify novel gene involved in familial breast cancer

An international research consortium led by Dr Jordi Surrallés, director of the Genetics Service at the Hospital de Sant Pau and professor of Genetics at the UAB, and by Dr Miquel Àngel Pujana, director of the ProCURE Research Programme of the Catalan Institute of Oncology, has identified a novel gene involved in this type of cancer, known as EDC4.

14 Mar 2018

Stem cells remain healthy following low-dose X-ray exposure, say biophysicists

Biophysicists have shown that following low-dose exposure to X-rays (at 80 milligrays), stem cells remain healthy, proliferate, and do not accumulate DNA damage to be passed on to their progeny. The paper was published in the journal Aging.

20 Dec 2017

Mutational patterns could identify breast cancer patients most likely to respond to platinum-based chemotherapy

The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy.

19 Dec 2017

Researchers unlock genetic processes underlying cancer

For many, breast cancer is more than just a disease – it's personal. One in eight women will be diagnosed with breast cancer at some point in their lives. But through new discoveries at the genetic level, the personal nature of cancer will eventually be what helps to beat it.

29 Nov 2017

Study: Maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer

Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Scientists question CRISPR human embryo editing claims

A paper published in the journal Nature on the 2nd August described how a gene editing tool CRISPR could be used to correct a genetic mutation that leads to a heart condition. This team had performed the genetic editing on the gene sequences in dozens of viable human embryos to attempt to prevent a genetic heart condition called hypertrophic cardiomyopathy.

31 Aug 2017

Scientists uncover stem cell response to prolonged irradiation

Researchers from several Russian institutes, including MIPT, have found out how prolonged exposure to ionizing radiation affects human stem cells.

24 Aug 2017

Researchers identify DNA repair deficiency in many types of solid tumors

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

18 May 2017

Penn researchers use CRISPR/Cas9 gene targeting approach to treat hemophilia B in mice

CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations.

1 Dec 2016

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

8 Oct 2016

Tumour suppressor gene has greater anti-cancer activity than previously thought

New insight into the function of a gene important in the suppression of cancer is published today. Researchers at the National University of Ireland Galway have shown that the TP53 gene has even greater anti-cancer activity than previously thought.

22 Sep 2016

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors.

5 Sep 2016